Aave Proposes Establishment of Unified Listing Standard: High-Risk Assets or Restricted Listing and Scalability
BlockBeats News, May 29, Aave Labs has initiated a new proposal to establish a unified asset technical review framework for Aave V3, V4, and Horizon, setting standardized review mechanisms for new asset listing, existing asset scalability, and ongoing asset retention.
The proposal states that all future assets must meet various technical requirements, including ERC20 compatibility, oracle reliability, bridge security, permission controls, minting mechanisms, audit status, and introduces continuous monitoring to ensure long-term compliance with protocol security standards.
Aave emphasizes that this framework aims to address the "hidden risks" associated with some assets, such as infinite minting, weak upgradeability permissions, inconsistent bridge supplies, opaque redemption paths, and off-chain custody dependencies. While these issues may not necessarily be reflected in market data, they could directly threaten the protocol's solvency, liquidation system, and collateral parameters security.
According to the proposal, assets with significant technical flaws may face reduced borrowing limits, collateral parameter restrictions, delayed listing, or even be recommended for protocol rejection.
The framework also specifically highlights additional reviews for cross-chain assets, yield-bearing assets, and RWA-type off-chain dependent assets, including bridge structures, off-chain legal arrangements, custody mechanisms, and supply integrity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
